These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17325711)

  • 1. The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element.
    Friedlich AL; Tanzi RE; Rogers JT
    Mol Psychiatry; 2007 Mar; 12(3):222-3. PubMed ID: 17325711
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease.
    Deng H; Xie W; Guo Y; Le W; Jankovic J
    Mov Disord; 2006 May; 21(5):728-9. PubMed ID: 16552756
    [No Abstract]   [Full Text] [Related]  

  • 3. [Relationship between alpha-synuclein and Parkinson's disease].
    Nishioka K; Hattori N
    Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors.
    Kao SY
    Biochem Biophys Res Commun; 2009 Jul; 385(3):434-8. PubMed ID: 19470380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.
    Halliday GM; McCann H
    Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological and pathological properties of alpha-synuclein.
    Tofaris GK; Spillantini MG
    Cell Mol Life Sci; 2007 Sep; 64(17):2194-201. PubMed ID: 17605001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population.
    Myhre R; Toft M; Kachergus J; Hulihan MM; Aasly JO; Klungland H; Farrer MJ
    Acta Neurol Scand; 2008 Nov; 118(5):320-7. PubMed ID: 18485051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
    Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
    J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of alpha-synuclein mRNA in Parkinson's disease.
    Papapetropoulos S; Adi N; Mash DC; Shehadeh L; Bishopric N; Shehadeh L
    Mov Disord; 2007 May; 22(7):1057-9; author reply 1057. PubMed ID: 17373725
    [No Abstract]   [Full Text] [Related]  

  • 11. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
    Kumar S; Sarkar A; Sundar D
    Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The family of iron responsive RNA structures regulated by changes in cellular iron and oxygen.
    Leipuviene R; Theil EC
    Cell Mol Life Sci; 2007 Nov; 64(22):2945-55. PubMed ID: 17849083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-Synuclein gene duplications in sporadic Parkinson disease.
    Theuns J; Van Broeckhoven C
    Neurology; 2008 Jan; 70(1):7-9. PubMed ID: 18166703
    [No Abstract]   [Full Text] [Related]  

  • 15. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence for differential methylation of α-synuclein in leukocyte DNA of Parkinson's disease patients.
    Richter J; Appenzeller S; Ammerpohl O; Deuschl G; Paschen S; Brüggemann N; Klein C; Kuhlenbäumer G
    Mov Disord; 2012 Apr; 27(4):590-1. PubMed ID: 22262231
    [No Abstract]   [Full Text] [Related]  

  • 17. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
    Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
    Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease.
    Troiano AR; Cazeneuve C; Le Ber I; Bonnet AM; Lesage S; Brice A
    Neurology; 2008 Oct; 71(16):1295; author reply 1295. PubMed ID: 18852449
    [No Abstract]   [Full Text] [Related]  

  • 19. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases.
    Cahill CM; Lahiri DK; Huang X; Rogers JT
    Biochim Biophys Acta; 2009 Jul; 1790(7):615-28. PubMed ID: 19166904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease.
    Brueggemann N; Odin P; Gruenewald A; Tadic V; Hagenah J; Seidel G; Lohmann K; Klein C; Djarmati A
    Neurology; 2008 Oct; 71(16):1294; author reply 1294. PubMed ID: 18852448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.